Compare VIR & BTZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VIR | BTZ |
|---|---|---|
| Founded | 2016 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 825.0M | 1.0B |
| IPO Year | 2019 | N/A |
| Metric | VIR | BTZ |
|---|---|---|
| Price | $5.95 | $10.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $25.73 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 279.4K |
| Earning Date | 11-05-2025 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.40% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.41 |
| Revenue | ★ $16,860,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $46.25 | N/A |
| P/E Ratio | ★ N/A | $7.57 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $4.16 | $9.10 |
| 52 Week High | $14.45 | $11.13 |
| Indicator | VIR | BTZ |
|---|---|---|
| Relative Strength Index (RSI) | 46.07 | 45.24 |
| Support Level | $5.73 | $10.75 |
| Resistance Level | $6.16 | $10.86 |
| Average True Range (ATR) | 0.33 | 0.06 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 16.53 | 39.29 |
Vir Biotechnology Inc is an immunology company focused on combining cutting-edge technologies to treat and prevent serious infectious diseases and other serious conditions, including viral-associated diseases. Through internal development, collaborations, and acquisitions, it has four technology platforms, focused on antibodies, T cells, innate immunity, and small interfering ribonucleic acid, or siRNA. The company's pipeline consists of product candidates targeting hepatitis B, HBV, influenza A, human immunodeficiency virus, HIV, and tuberculosis, or TB. Its revenue sources are collaboration revenue, contract revenue, grant revenue, and license revenue.
Blackrock Credit Allocation Income Trust is a diversified, closed-end Trust engaged in providing investment advisory and risk management solutions. Its investment objective is to seek current income, current gains, and capital appreciation. The company invests under normal market conditions, at least 80% of its assets in credit-related securities, including, but not limited to, investment-grade corporate bonds, high-yields, bank loans, preferred securities or convertible bonds, or derivatives with economic characteristics similar to these credit-related securities.